Qureshi A A, Bradlow B A, Brace L, Manganello J, Peterson D M, Pearce B C, Wright J J, Gapor A, Elson C E
Advanced Medical Research, Madison, Wisconsin 53719, USA.
Lipids. 1995 Dec;30(12):1171-7. doi: 10.1007/BF02536620.
The cholesterol-suppressive actions of Palmvitee and gamma-tocotrienol were assessed in hypercholesterolemic subjects after acclimation to the American Heart Association Step 1 dietary regimen for four and eight weeks, respectively. The four-week dietary regimen alone elicited a 5% decrease (P < 0.05) in the cholesterol level of the 36 subjects. Subjects continuing on the dietary regimen for a second four-week period experienced an additional 2% decrease in their cholesterol levels. Dietary assessments based on unanticipated recalls of 24-h food intake records suggest that significant reductions in energy and fat, predominantly in saturated fat, intakes are responsible. The subjects experienced significant Palmvitee- and gamma-tocotrienol-mediated decreases in cholesterol. The group of subjects acclimated to the dietary regimen for four weeks responded to Palmvitee (a blend of tocols providing 40 mg alpha-tocopherol, 48 mg alpha-tocotrienol, 112 mg gamma-tocotrienol, and 60 mg delta-to-cotrienol/day for four weeks) with a 10% decrease in cholesterol (P < 0.05). Dietary assessments showed no further change in energy and fat intakes. alpha-Tocopherol attenuated the cholesterol-suppressive action of the tocotrienols. The second group of subjects, acclimated to the dietary regimen for eight weeks, received 200 mg gamma-tocotrienol/d for four weeks. The cholesterol-suppressive potency of this alpha-tocopherol-free preparation was calculated to be equivalent to that of the mixture of tocotrienols (220 mg) used in the prior study. Cholesterol levels of the 16 subjects in the second group decreased 13% (P < 0.05) during the four-week trial. Plasma apolipoprotein B and ex vivo generation of thromboxane B2 were similarly responsive to the tocotrienol preparations, whereas neither preparation had an impact on high density lipoprotein cholesterol and apolipoprotein A-1 levels.
分别在适应美国心脏协会第一步饮食方案四周和八周后的高胆固醇血症受试者中，评估了Palmvitee和γ-生育三烯酚对胆固醇的抑制作用。仅四周的饮食方案就使36名受试者的胆固醇水平降低了5%（P<0.05）。继续进行第二个四周饮食方案的受试者胆固醇水平又降低了2%。基于对24小时食物摄入记录的意外回忆进行的饮食评估表明，能量和脂肪摄入量的显著减少，主要是饱和脂肪摄入量的减少，是造成这种情况的原因。受试者的胆固醇水平因Palmvitee和γ-生育三烯酚而显著降低。适应四周饮食方案的受试者组对Palmvitee（一种生育酚混合物，连续四周每天提供40毫克α-生育酚、48毫克α-生育三烯酚、112毫克γ-生育三烯酚和60毫克δ-生育三烯酚）的反应是胆固醇降低10%（P<0.05）。饮食评估显示能量和脂肪摄入量没有进一步变化。α-生育酚减弱了生育三烯酚的胆固醇抑制作用。第二组适应八周饮食方案的受试者，连续四周每天服用200毫克γ-生育三烯酚。计算得出，这种不含α-生育酚的制剂对胆固醇的抑制效力与先前研究中使用的生育三烯酚混合物（220毫克）相当。在为期四周的试验中，第二组16名受试者的胆固醇水平下降了13%（P<0.05）。血浆载脂蛋白B和血栓素B2的体外生成对生育三烯酚制剂有类似反应，而两种制剂对高密度脂蛋白胆固醇和载脂蛋白A-1水平均无影响。
